What is the 13F Pro Quality Score for ACHC?

13F Pro ranks Acadia Healthcare Company, Inc. (ACHC) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View ACHC's current score at https://13fpro.ai/research/ACHC (free sign-up required for the full ranking).

Which hedge funds own the most ACHC stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of ACHC include BlackRock,, WELLINGTON MANAGEMENT GROUP LLP, FMR. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/ACHC as soon as new 13F filings post.

Where does 13F Pro source ACHC data?

All Acadia Healthcare Company, Inc. fundamentals and ownership data come directly from SEC EDGAR. Acadia Healthcare Company, Inc. files with the SEC under CIK 1520697. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is ACHC in?

Acadia Healthcare Company, Inc. (ACHC) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is ACHC research updated on 13F Pro?

ACHC's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Acadia Healthcare Company, Inc.(ACHC)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1520697 ACHC stock profile & AI dashboard →

13F Pro Quality Score

49.3/100

Rank #1,515 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

54.4/100

Profitability

53.0/100

Balance Sheet

47.5/100

Earnings Quality

30.0/100

Free Cash Flow

20.5/100

Institutional Flow

48.6/100

Revenue Scale

71.8/100

Dilution Risk

57.9/100

ACHC Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Acadia Healthcare Company, Inc. (ACHC), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ACHC at 49.3/100 on a 32-signal composite quality model, placing it at rank #1,515 of 2,879 stocks — the bottom half of the AI-ranked universe. Areas of concern include free cash flow (20.5) and earnings quality (30.0), which score below median versus the broader universe. Based on the latest XBRL financial filings (Q1 2026), Acadia Healthcare Company, Inc. reports quarterly revenue of $828.8M, net income of $4.1M, free cash flow of $-15.0M. Top institutional holders of ACHC by reported 13-F value include BlackRock,, WELLINGTON MANAGEMENT GROUP LLP, FMR, based on the most recent SEC filings. ACHC trades on the Nasdaq exchange and files with the SEC under CIK 1520697. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ACHC daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Acadia Healthcare Company, Inc. directly from SEC EDGAR. Acadia Healthcare Company, Inc.'s 13F Pro composite quality score has ranged between 8 and 67 since 2021, currently 49.3 — an improving long-term trajectory across 56 quarterly and live scoring snapshots.

Revenue

Q1 2026

$828.8M

Net Income

Q1 2026

$4.1M

Free Cash Flow

Q1 2026

$-15.0M

D/E Ratio

Q1 2026

1.31

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+5.0% YoY

$3.31BFY 2025

FY22 $2.61BFY23 $2.93BFY24 $3.15BFY25 $3.31B

Net Income

-531.4% YoY

$-1.10BFY 2025

FY22 $273.1MFY23 $-21.7MFY24 $255.6MFY25 $-1.10B

Operating Income

—FY 2025

FY22 —FY23 —FY24 —FY25 —

EPS (Diluted)

-537.4% YoY

$-12.16FY 2025

FY22 $2.98FY23 $-0.24FY24 $2.78FY25 $-12.16

Total Assets

-7.2% YoY

$5.53BFY 2025

FY22 $4.99BFY23 $5.36BFY24 $5.96BFY25 $5.53B

Total Debt

+24.3% YoY

$2.53BFY 2025

FY22 $1.41BFY23 $1.40BFY24 $2.03BFY25 $2.53B

Op. Cash Flow

+1.7% YoY

$131.9MFY 2025

FY22 $380.6MFY23 $462.3MFY24 $129.7MFY25 $131.9M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2019
Revenue	$3.31B +5.0%	$3.15B +7.7%	$2.93B +12.2%	$2.61B +12.8%	$2.31B +15.2%	$2.01B
Net Income	$-1.10B -531.4%	$255.6M +1279.7%	$-21.7M -107.9%	$273.1M +43.3%	$190.6M +75.0%	$108.9M
Operating Income	—	—	—	—	—	$585.9M
EPS (Diluted)	$-12.16 -537.4%	$2.78 +1258.3%	$-0.24 -108.1%	$2.98 +41.9%	$2.10 +69.4%	$1.24
Total Assets	$5.53B -7.2%	$5.96B +11.2%	$5.36B +7.4%	$4.99B +4.6%	$4.77B -30.7%	$6.88B
Total Debt	$2.53B +24.3%	$2.03B +45.2%	$1.40B -0.4%	$1.41B -7.2%	$1.52B -52.5%	$3.19B
Operating Cash Flow	$131.9M +1.7%	$129.7M -71.9%	$462.3M +21.5%	$380.6M +1.6%	$374.5M +12.5%	$332.9M

AI Insight: ACHC Financial Trends

Acadia Healthcare suffered a massive $1.2B net loss in Q4 2025, driving equity down 38% and debt up $200M over the quarter.

• Revenue grew from $796M in Q2 2024 to $829M in Q1 2026, but with significant quarterly volatility.

• Net income collapsed from $36M in Q3 2025 to -$1,178M in Q4 2025, recovering slightly to $4M in Q1 2026.

• Total debt increased from $1,908M in Q2 2024 to $2,559M in Q1 2026, rising $194M in Q4 2025 alone.

• Equity dropped from $3,120M in Q3 2025 to $1,949M in Q4 2025, a $1.2B decline.

⚠ Operating cash flow turned negative to -$86M in Q4 2025 after multiple positive quarters.

⚠ Q1 2026 shows early signs of stabilization with positive net income and operating cash flow recovery.

AI Insight: ACHC Ratio Trends

ACHC suffered catastrophic Q4 2025 losses with -142% operating margin, pushing TTM profitability deeply negative despite Q1 2026 recovery signs.

• Operating margin collapsed from 12.1% in Q3 2024 to -142.4% in Q4 2025 before recovering to 1.3% in Q1 2026.

• ROE deteriorated from 10.6% in Q2 2024 to 0.8% in Q1 2026, with TTM ROE at -56.5%.

• Debt-to-equity ratio doubled from 0.65 in Q2 2024 to 1.31 in Q1 2026.

⚠ Q1 2026 showed modest margin recovery to 1.3% after Q4 2025's devastating -142.4% operating margin.

⚠ Leverage spike to 1.31 D/E from Q4 2025 onwards versus 0.64-0.75 range in prior quarters.

Get alerted when ACHC's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Acadia Healthcare Company, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of ACHC

BlackRock, Inc.
$273.3M11,686,389 sh
WELLINGTON MANAGEMENT GROUP LLP
$212.2M9,072,942 sh
FMR LLC
$160.6M6,867,678 sh
Khrom Capital Management LLC
$121.5M5,194,625 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$118.4M5,061,438 sh
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
$105.7M4,520,000 sh
DME Capital Management, LP
$105.7M4,518,381 sh
MORGAN STANLEY
$105.0M4,491,067 sh
ABRAMS BISON INVESTMENTS, LLC
$102.4M4,380,000 sh
VANGUARD CAPITAL MANAGEMENT LLC
$97.2M4,154,801 sh

Fund	Value	Shares
BlackRock, Inc.	$273.3M	11,686,389
WELLINGTON MANAGEMENT GROUP LLP	$212.2M	9,072,942
FMR LLC	$160.6M	6,867,678
Khrom Capital Management LLC	$121.5M	5,194,625
VANGUARD PORTFOLIO MANAGEMENT LLC	$118.4M	5,061,438
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)	$105.7M	4,520,000
DME Capital Management, LP	$105.7M	4,518,381
MORGAN STANLEY	$105.0M	4,491,067
ABRAMS BISON INVESTMENTS, LLC	$102.4M	4,380,000
VANGUARD CAPITAL MANAGEMENT LLC	$97.2M	4,154,801

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put ACHC on your watchlist

Track score changes the day Acadia Healthcare Company, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is ACHC a good stock to buy?

13F Pro's AI-powered analysis of Acadia Healthcare Company, Inc. (ACHC) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ACHC are available on the ACHC stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own ACHC?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ACHC. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Acadia Healthcare Company, Inc.'s investment landscape.